FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 6, 2014--
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Kevin Young
CBE, Executive Vice President, Commercial Operations, has informed the
company of his decision to retire, effective February 4th. Mr. Young
will continue to work directly with Gilead’s management team as a senior
advisor.
Mr. Young joined Gilead in 2004 to lead the company’s global commercial
operations. During his tenure, he oversaw the launch of eight new
therapies, including the first single tablet regimen for the treatment
of HIV which is now the best-selling brand-named HIV product in the
United States and European Union. In addition, Mr. Young has spent the
last two years preparing Gilead for the introduction of a novel oral
antiviral for the treatment of chronic hepatitis C. Mr. Young also
managed significant expansion of Gilead’s operations in North America,
Europe and Asia, including the establishment of new affiliate offices in
Poland, Russia, South Korea and Japan. Under Mr. Young’s leadership,
Gilead’s annual revenues grew from $1.24 billion in 2004 to nearly $10
billion in 2012.
“Kevin’s impact on the entire Gilead organization has been tremendous,
and on behalf of the company’s senior management team and board of
directors, I thank him for his dedication and commitment to excellence,”
said John Martin, PhD, Chairman and Chief Executive Officer, Gilead
Sciences. “Over the past nine years, he has greatly expanded and
strengthened our commercial organization, preparing the company to
introduce products in new therapeutic areas and ensuring a consistent
and clear focus on the needs of patients around the world. I have deeply
valued his insights and perspectives, and look forward to a continued
partnership as Kevin remains with Gilead in an advisory role.”
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North and South America, Europe and
Asia Pacific.
Forward-Looking Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2013, as filed
with the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Gilead, and
Gilead assumes no obligation to update any such forward-looking
statements.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.Patrick O’Brien, 650-522-1936 (Investors)Cara
Miller, 650-522-1616 (Media)
